AR090994A1 - Uracilos sustituidos biciclicamente y uso de los mismos - Google Patents
Uracilos sustituidos biciclicamente y uso de los mismosInfo
- Publication number
- AR090994A1 AR090994A1 ARP130101600A ARP130101600A AR090994A1 AR 090994 A1 AR090994 A1 AR 090994A1 AR P130101600 A ARP130101600 A AR P130101600A AR P130101600 A ARP130101600 A AR P130101600A AR 090994 A1 AR090994 A1 AR 090994A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- hydrogen
- halogen
- difluoromethyl
- trifluoromethyl
- Prior art date
Links
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 229910052739 hydrogen Inorganic materials 0.000 abstract 6
- 239000001257 hydrogen Substances 0.000 abstract 6
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 abstract 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 abstract 2
- GHMVTBRBCJHSKM-UHFFFAOYSA-N [N].O=C1C=CNC(=O)N1 Chemical group [N].O=C1C=CNC(=O)N1 GHMVTBRBCJHSKM-UHFFFAOYSA-N 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 125000004432 carbon atom Chemical group C* 0.000 abstract 2
- 229910052805 deuterium Inorganic materials 0.000 abstract 2
- 230000006806 disease prevention Effects 0.000 abstract 2
- 239000011737 fluorine Chemical group 0.000 abstract 2
- 229910052731 fluorine Chemical group 0.000 abstract 2
- 150000002431 hydrogen Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 1
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical class O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000000217 alkyl group Chemical group 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 125000002619 bicyclic group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- -1 trideuterometyl Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La presente solicitud se refiere a derivados de uracilo sustituidos bicíclicamente, a procedimientos de preparación de los mismos, al uso de los mismos solos o en combinaciones para el tratamiento y/o la prevención de enfermedades y al uso de los mismos para la producción de medicamentos para el tratamiento y/o la prevención de enfermedades. Reivindicación 1: Compuesto de la fórmula (1) en la que R¹ es hidrógeno o alquilo C₁₋₄; R² es un grupo de la fórmula (2), (3) ó (4) en la que * es el sitio de unión al átomo de nitrógeno del uracilo; A es -CH₂-, -CH₂-CH₂-, -O-CH₂-## u oxígeno, en el que ## es el sitio de unión al anillo de fenilo; m es el número 0, 1 ó 2; R⁴ es halógeno, difluorometilo, trifluorometilo, alquilo C₁₋₄, difluorometoxi, trifluorometoxi o alcoxi C₁₋₄; R⁵A es hidrógeno o deuterio; R⁵B es hidrógeno, deuterio o alquilo C₁₋₄; R⁶ es hidrógeno o flúor; R⁷ es hidrógeno o flúor; R⁸ es halógeno, difluorometilo, trifluorometilo, alquilo C₁₋₄ o nitro; R⁹ es hidrógeno, halógeno, difluorometilo, trifluorometilo, alquilo C₁₋₄, nitro o alquil C₁₋₄-tio; R³ es un grupo de la fórmula (5) en la que # es el sitio de unión al átomo de nitrógeno del uracilo; el anillo Q es heterociclo de 5 a 7 miembros o heteroarilo de 5 ó 6 miembros, en el que el heterociclo de 5 a 7 miembros o el heteroarilo de 5 ó 6 miembros puede estar sustituido con 1 a 4 sustituyentes seleccionados independientemente del grupo de halógeno, difluorometilo, trifluorometilo, trideuterometilo, alquilo C₁₋₆, cicloalquilo C₃₋₇, oxo, hidroxilo, alquil C₁₋₄-carbonilo, alcoxi C₁₋₄-carbonilo, aminocarbonilo y alquil C₁₋₄-sulfonilo, en el que el alquilo C₁₋₆ y el cicloalquilo C₃₋₇, ₐ ₛᵘ ᵛₑᶻ, ₚᵘₑᵈₑₙ ₑₛₜₐʳ ₛᵘₛₜⁱₜᵘⁱᵈₒₛ ᶜₒₙ ₁ ₐ ₃ ₛᵘₛₜⁱₜᵘʸₑₙₜₑₛ ₛₑₗₑᶜᶜⁱₒₙₐᵈₒₛ ⁱₙᵈₑₚₑₙᵈⁱₑₙₜₑₘₑₙₜₑ ᵈₑₗ ᵍʳᵘₚₒ ᵈₑ ₕₐₗóᵍₑₙₒ, ᶜⁱₐₙₒ, ₜʳⁱᶠₗᵘₒʳₒₘₑₜⁱₗₒ, ᶜⁱᶜₗₒₐₗqᵘⁱₗₒ C₃₋₇, hidroxilo, alcoxi C₁₋₄ y heterociclo de 4 a 7 miembros, y en el que dos radicales alquilo C₁₋₆ unidos a un átomo de carbono del heterociclo de 5 a 7 miembros y el heteroarilo de 5 ó 6 miembros, junto con el átomo de carbono al que están unidos, pueden formar un carbociclo de 3 a 6 miembros; R²⁴ es halógeno, alquilo C₁₋₄ o alcoxi C₁₋₄; n es el número 0, 1, 2 ó 3; y las sales, solvatos y solvatos de las sales del mismo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167231 | 2012-05-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR090994A1 true AR090994A1 (es) | 2014-12-30 |
Family
ID=48289199
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130101600A AR090994A1 (es) | 2012-05-09 | 2013-05-08 | Uracilos sustituidos biciclicamente y uso de los mismos |
Country Status (43)
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
| AU2014345599B2 (en) * | 2013-11-08 | 2019-02-14 | Bayer Pharma Aktiengesellschaft | Salts of 1-(3-Methyl-2-oxo-2,3-dihydro-1,3-benzoxazol-6-yl)-2,4-dioxo-3-[(1R)- 4-(trifluormethyl)-2,3-dihydro-1H-inden-1-yl]-1,2,3,4-tetrahydropyrimidin-5-carboxylic acid |
| HK1224288A1 (zh) * | 2013-11-08 | 2017-08-18 | Bayer Pharma Aktiengesellschaft | 作为类糜蛋白酶抑制剂的取代的尿嘧啶 |
| HK1223610A1 (zh) * | 2013-11-08 | 2017-08-04 | Bayer Pharma Aktiengesellschaft | 取代的1，2，4-三嗪-3，5-二酮及其作为类糜蛋白酶抑制剂的用途 |
| CA2929753A1 (en) | 2013-11-08 | 2015-05-14 | Bayer Pharma Aktiengesellschaft | Substituted uracils and use thereof |
| WO2017162661A1 (en) | 2016-03-22 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | 1h-benzo[de]isoquinoline-1,3(2h)-diones |
| EP3338780A1 (de) | 2016-12-20 | 2018-06-27 | Bayer Pharma Aktiengesellschaft | Verwendung von chymaseinhibitoren zur behandlung von endometriose, post-operativer fibrose und erkrankungen die durch fibrosebildung gekennzeichnet sind |
| WO2018197333A1 (en) | 2017-04-27 | 2018-11-01 | Bayer Aktiengesellschaft | Selective adrenoreceptor alpha2c receptor antagonists alone, or in combination with chymase inhibitors for use in the treatment and/or prophylaxis of peripheral artery diseases (pad) |
| KR20210008070A (ko) | 2018-05-15 | 2021-01-20 | 바이엘 악티엔게젤샤프트 | 신경 섬유 감작과 연관된 질환의 치료를 위한 1,3-티아졸-2-일 치환된 벤즈아미드 |
| CN110229067A (zh) * | 2019-06-05 | 2019-09-13 | 南京焕然生物科技有限公司 | 一种2-氨基茚制备方法 |
| WO2021000933A1 (zh) * | 2019-07-03 | 2021-01-07 | 南京明德新药研发有限公司 | 作为糜酶抑制剂的嘧啶酮类化合物及其应用 |
| US11618751B1 (en) | 2022-03-25 | 2023-04-04 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives |
| CN111440141A (zh) * | 2020-05-20 | 2020-07-24 | 安徽泽升科技有限公司 | 一种羟甲基取代芳杂环类化合物的制备方法 |
| CN114685472B (zh) * | 2020-12-25 | 2024-04-26 | 广东东阳光药业股份有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| WO2022135502A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 多取代的尿嘧啶衍生物及其用途 |
| WO2022135534A1 (zh) * | 2020-12-25 | 2022-06-30 | 广东东阳光药业有限公司 | 取代的含氮双环化合物及其用途 |
| US11319319B1 (en) | 2021-04-07 | 2022-05-03 | Ventus Therapeutics U.S., Inc. | Compounds for inhibiting NLRP3 and uses thereof |
| WO2023107490A1 (en) * | 2021-12-06 | 2023-06-15 | Pretzel Therapeutics, Inc. | Heterocycle-containing lonp1 inhibitor compounds, uses and methods |
| JP2025511834A (ja) | 2022-04-05 | 2025-04-16 | ソクプラ シオンス ソンテ エ ユーメン エス．ウ．シ． | 血栓性または血栓塞栓性障害における血栓の選択的溶解に使用するためのキマーゼの阻害剤 |
| US12331048B2 (en) | 2022-10-31 | 2025-06-17 | Ventus Therapeutics U.S., Inc. | Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6403599B1 (en) * | 1995-11-08 | 2002-06-11 | Pfizer Inc | Corticotropin releasing factor antagonists |
| US6114532A (en) | 1998-02-03 | 2000-09-05 | Boehringer Ingelheim Pharma Kg | Bicyclic heterocycles, the preparation thereof, and their use as pharmaceuticals |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| US6458952B1 (en) | 1999-05-19 | 2002-10-01 | Pharmacia Corporation | Substituted polycyclic aryl and heteroaryl uracils useful for selective inhibition of the coagulation cascade |
| WO2001017980A1 (en) | 1999-09-03 | 2001-03-15 | Ajinomoto Co., Inc. | Novel processes for preparing oxazepine derivatives |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| GB0021315D0 (en) * | 2000-08-30 | 2000-10-18 | Dainippon Pharmaceutical Co | Heterocyclic compounds and intermediates thereof |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| JP2003017508A (ja) | 2001-07-05 | 2003-01-17 | Nec Corp | 電界効果トランジスタ |
| AR038536A1 (es) | 2002-02-25 | 2005-01-19 | Upjohn Co | N-aril-2-oxazolidinona-5- carboxamidas y sus derivados |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| JP2003342265A (ja) * | 2002-05-22 | 2003-12-03 | Senju Pharmaceut Co Ltd | トリアゾリジン誘導体およびその医薬用途 |
| WO2004052858A2 (en) | 2002-12-06 | 2004-06-24 | Eli Lilly And Company | Inhibitors of monoamine uptake |
| AU2004266536A1 (en) * | 2003-08-22 | 2005-03-03 | Teijin Pharma Limited | Drug containing chymase inhibitor as the active ingredient |
| DE102004004928A1 (de) | 2004-01-31 | 2005-08-18 | Bayer Healthcare Ag | Dibenzoxazepine II |
| KR101258504B1 (ko) | 2004-03-26 | 2013-04-26 | 메틸진 인코포레이티드 | 히스톤 데아세틸라제의 억제제 |
| US7507748B2 (en) | 2004-07-22 | 2009-03-24 | Amgen Inc. | Substituted aryl-amine derivatives and methods of use |
| JP5197016B2 (ja) | 2004-12-23 | 2013-05-15 | デシファラ ファーマスーティカルズ， エルエルシー | 酵素モジュレータ及び治療 |
| EP1885369B1 (en) | 2005-05-04 | 2015-09-23 | Evotec AG | Fused heterocyclic compounds, and compositions and uses thereof |
| WO2007007161A2 (en) * | 2005-07-08 | 2007-01-18 | Orchid Research Laboratories Limited | Novel bio-active derivatives |
| JP2009520038A (ja) | 2005-12-19 | 2009-05-21 | ジェネンテック・インコーポレーテッド | ピリミジンキナーゼインヒビター |
| CA2642406A1 (en) | 2006-02-14 | 2007-08-23 | Pfizer Products Inc. | Benzoxazinone and benzoxazepinone oxazolidinones as antibacterial agents |
| JO2934B1 (en) * | 2006-06-23 | 2015-09-15 | سميث كلاين بيتشام كوربوريشن | Prolyl hydroxylase inhibitors |
| US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
| GB0622472D0 (en) | 2006-11-10 | 2006-12-20 | Addex Pharmaceuticals Sa | Novel heterocyclic derivatives |
| MX2009008531A (es) | 2007-02-16 | 2009-08-26 | Amgen Inc | Cetonas de heterociclilo que contienen nitrogeno y su uso como inhibidores de c-met. |
| MX2009011059A (es) | 2007-04-13 | 2009-11-26 | Vertex Pharma | Aminopirimidinas utiles como inhibidores de cinasas. |
| WO2009049112A1 (en) | 2007-10-10 | 2009-04-16 | Smithkline Beecham Corporation | Prolyl hydroxylase inhibitors |
| RU2500681C2 (ru) | 2007-10-19 | 2013-12-10 | Берингер Ингельхайм Интернациональ Гмбх | Замещенные гетероциклом пиперазинодигидротиенопиримидины |
| JP4790871B2 (ja) * | 2008-05-05 | 2011-10-12 | メルク フロスト カナダ リミテツド | レニン阻害剤としての３，４−置換ピペリジン誘導体 |
| ES2516716T3 (es) | 2008-06-25 | 2014-10-31 | Daiichi Sankyo Company, Limited | Compuesto de ácido carboxílico |
| DE102008030091B4 (de) | 2008-06-25 | 2011-03-03 | Resprotect Gmbh | Uracilderivate und deren Verwendung |
| UA112897C2 (uk) * | 2012-05-09 | 2016-11-10 | Байєр Фарма Акцієнгезелльшафт | Біциклічно заміщені урацили та їх застосування для лікування і/або профілактики захворювань |
-
2013
- 2013-03-05 UA UAA201413167A patent/UA112897C2/uk unknown
- 2013-05-03 NO NO16154186A patent/NO3045456T3/no unknown
- 2013-05-03 EP EP13720407.9A patent/EP2847190B1/de active Active
- 2013-05-03 SG SG10202003175QA patent/SG10202003175QA/en unknown
- 2013-05-03 PE PE2014001986A patent/PE20142301A1/es active IP Right Grant
- 2013-05-03 ES ES13720407.9T patent/ES2581537T3/es active Active
- 2013-05-03 WO PCT/EP2013/059286 patent/WO2013167495A1/de not_active Ceased
- 2013-05-03 MX MX2018008811A patent/MX367599B/es unknown
- 2013-05-03 PT PT137204079T patent/PT2847190T/pt unknown
- 2013-05-03 BR BR112014028086-0A patent/BR112014028086B1/pt active IP Right Grant
- 2013-05-03 EA EA201790032A patent/EA031222B1/ru not_active IP Right Cessation
- 2013-05-03 CA CA2872906A patent/CA2872906C/en active Active
- 2013-05-03 CN CN201710219097.9A patent/CN106983751B/zh active Active
- 2013-05-03 DK DK16154186.7T patent/DK3045456T3/da active
- 2013-05-03 HR HRP20160796TT patent/HRP20160796T1/hr unknown
- 2013-05-03 US US14/399,945 patent/US9481672B2/en active Active
- 2013-05-03 EA EA201492040A patent/EA030383B9/ru not_active IP Right Cessation
- 2013-05-03 AU AU2013258223A patent/AU2013258223B2/en active Active
- 2013-05-03 DK DK13720407.9T patent/DK2847190T3/en active
- 2013-05-03 JP JP2015510754A patent/JP6141414B2/ja active Active
- 2013-05-03 CN CN201380034776.9A patent/CN104395310B/zh active Active
- 2013-05-03 MX MX2014013571A patent/MX357712B/es active IP Right Grant
- 2013-05-03 HU HUE13720407A patent/HUE029366T2/en unknown
- 2013-05-03 PT PT161541867T patent/PT3045456T/pt unknown
- 2013-05-03 NZ NZ701700A patent/NZ701700A/en unknown
- 2013-05-03 SI SI201330934T patent/SI3045456T1/en unknown
- 2013-05-03 LT LTEP16154186.7T patent/LT3045456T/lt unknown
- 2013-05-03 EP EP16154186.7A patent/EP3045456B1/de active Active
- 2013-05-03 KR KR1020147034155A patent/KR102083281B1/ko active Active
- 2013-05-03 HU HUE16154186A patent/HUE035462T2/en unknown
- 2013-05-03 PL PL16154186T patent/PL3045456T3/pl unknown
- 2013-05-03 MY MYPI2014703273A patent/MY181828A/en unknown
- 2013-05-03 PL PL13720407.9T patent/PL2847190T3/pl unknown
- 2013-05-03 AP AP2014008096A patent/AP2014008096A0/xx unknown
- 2013-05-03 SI SI201330233A patent/SI2847190T1/sl unknown
- 2013-05-03 ES ES16154186.7T patent/ES2657315T3/es active Active
- 2013-05-03 RS RS20160510A patent/RS54901B1/sr unknown
- 2013-05-03 RS RS20180076A patent/RS56784B1/sr unknown
- 2013-05-08 SA SA113340533A patent/SA113340533B1/ar unknown
- 2013-05-08 TW TW106105676A patent/TWI635085B/zh active
- 2013-05-08 JO JOP/2013/0144A patent/JO3290B1/ar active
- 2013-05-08 AR ARP130101600A patent/AR090994A1/es active IP Right Grant
- 2013-05-08 UY UY0001034797A patent/UY34797A/es active IP Right Grant
- 2013-05-08 TW TW102116308A patent/TWI579278B/zh active
-
2014
- 2014-11-02 IL IL235438A patent/IL235438A/en active IP Right Grant
- 2014-11-06 CU CU2014000129A patent/CU20140129A7/es unknown
- 2014-11-07 EC ECIEPI201426138A patent/ECSP14026138A/es unknown
- 2014-11-07 DO DO2014000255A patent/DOP2014000255A/es unknown
- 2014-11-07 ZA ZA2014/08146A patent/ZA201408146B/en unknown
- 2014-11-07 CL CL2014003031A patent/CL2014003031A1/es unknown
- 2014-11-07 PH PH12014502496A patent/PH12014502496A1/en unknown
- 2014-11-07 CO CO14246970A patent/CO7131375A2/es unknown
- 2014-11-07 TN TN2014000470A patent/TN2014000470A1/fr unknown
- 2014-11-07 CR CR20140513A patent/CR20140513A/es unknown
-
2016
- 2016-07-06 CY CY20161100636T patent/CY1118900T1/el unknown
- 2016-10-07 US US15/288,982 patent/US9949978B2/en active Active
- 2016-10-07 US US15/288,968 patent/US9949977B2/en active Active
-
2017
- 2017-05-02 JP JP2017091842A patent/JP6367421B2/ja active Active
- 2017-08-10 IL IL253950A patent/IL253950B/en active IP Right Grant
- 2017-11-22 AU AU2017265047A patent/AU2017265047B2/en active Active
-
2018
- 2018-01-23 HR HRP20180125TT patent/HRP20180125T1/hr unknown
- 2018-01-24 CY CY20181100095T patent/CY1119840T1/el unknown
- 2018-03-05 US US15/912,185 patent/US10300062B2/en active Active
-
2019
- 2019-04-02 US US16/373,487 patent/US20200061063A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR090994A1 (es) | Uracilos sustituidos biciclicamente y uso de los mismos | |
| JOP20130256B1 (ar) | مركبات سلفامويل اريل اميدات واستعمالها كمواد علاجية لمعالجة التهاب الكبد نوع بي | |
| AR109295A1 (es) | Compuestos tricíclicos que contienen nitrógeno y usos de los mismos en medicina | |
| AR093364A1 (es) | Imidazo[1,2-a]piridincarboxamidas aminosustituidas y su uso | |
| AR097756A1 (es) | Derivados de fenilalanina sustituidos | |
| AR109805A1 (es) | Derivados de oxadiazol microbiocidas | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| PH12015500386A1 (en) | Fused bicyclic sulfamoyl derivatives and the use thereof as medicaments for the treatment of hepatitis b | |
| AR088175A1 (es) | 3-pirimidin-4-il-oxazolidin-2-onas utiles para tratar cancer y composiciones farmaceuticas que las contienen | |
| EA201591703A1 (ru) | Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина | |
| JO3603B1 (ar) | مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي | |
| AR089776A1 (es) | 5,8-dihidro-6h-pirazolo[3,4-h]quinazolinas como inhibidores de igf-1r/ir | |
| AR094174A1 (es) | Lactamas fusionadas de arilo y heteroarilo | |
| BR112013016856A2 (pt) | composto, uso de um composto, composição farmacêutica e produto farmacêutico | |
| EA201590023A1 (ru) | Новые 4-замещенные производные 1,3-дигидро-2h-бензимидазол-2-она, замещенные бензимидазолами, в качестве противовирусных средств против респираторного синцитиального вируса | |
| AR090670A1 (es) | Compuestos herbicidas | |
| AR103232A1 (es) | ANTAGONISTAS DE TGFbR | |
| EA201390163A1 (ru) | Гетеробициклические производные в качетстве ингибиторов hcv | |
| AR084152A1 (es) | Compuestos de triazolopirimidina como inhibidores de pde10a, un proceso para su obtencion, composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades del snc | |
| AR098492A1 (es) | Derivados de purina | |
| AR097755A1 (es) | Derivados sustituidos de fenilalanina como moduladores del factor xia | |
| AR097754A1 (es) | Derivados sustituidos de fenilalanina | |
| AR093408A1 (es) | Derivados de oxazolidin-2-ona-pirimidina | |
| AR091185A1 (es) | Derivados de 1,2,4-triazol | |
| UA117490C2 (uk) | Сполуки ізоіндоліну або ізохіноліну, спосіб їх одержання і фармацевтичні композиції, що їх містять |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |